New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDihexa vs Eloralintide

Dihexa vs Eloralintide

Side-by-side comparison of key properties, dosing, and research.

Cognitive Enhancement
Dihexa
GLP-1 / Weight Loss Agonists
Eloralintide
Summary
Dihexa is a potent experimental oligopeptide derived from angiotensin IV that dramatically enhances synaptogenesis. Preclinical research shows cognitive enhancement orders of magnitude more potent than BDNF — it is considered one of the most powerful nootropic compounds in research, but has very limited human safety data.
Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
Half-Life
Unknown (limited pharmacokinetic data)
~7 days (estimated, long-acting design)
Admin Route
Oral, SubQ, Topical
SubQ
Research
Typical Dose
5–10 mg
Under investigation in Phase 1/2 trials
Frequency
Daily
Once weekly
Key Benefits
  • Dramatically increases synapse formation (potentially 10 million× more potent than BDNF in animal models)
  • Enhances memory and learning
  • May reverse cognitive decline
  • Improves neuroplasticity and executive function
  • Long-lasting cognitive benefits from short courses
  • Potential therapeutic agent for Alzheimer's
  • Once-weekly dosing (vs multiple daily injections for pramlintide)
  • Appetite suppression via central amylin receptor activation
  • Reduction in post-meal glucagon secretion
  • Complementary mechanism to GLP-1 agonists for combination therapy
  • Slows gastric emptying for prolonged satiety
  • Potential additive weight loss when combined with GLP-1 agents
Side Effects
  • Headache
  • Irritability
  • Brain fog during washout period
  • Unknown long-term effects (insufficient data)
  • Nausea
  • Vomiting
  • Decreased appetite
  • Injection site reactions
  • +1 more
Stacks With